Cargando…

Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy

INTRODUCTION: Superficial morphea (SM) is an uncommon entity that was described in the literature without definitive correlation to localized scleroderma (LS) or other atrophoderma diseases. AIM: To demonstrate the clinicopathological features of SM and evaluate the efficacy of different therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosbeh, Al-Sadat, Aboeldahab, Soha, El-Khalawany, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770326/
https://www.ncbi.nlm.nih.gov/pubmed/31641348
http://dx.doi.org/10.1155/2019/1967674
_version_ 1783455445985263616
author Mosbeh, Al-Sadat
Aboeldahab, Soha
El-Khalawany, Mohamed
author_facet Mosbeh, Al-Sadat
Aboeldahab, Soha
El-Khalawany, Mohamed
author_sort Mosbeh, Al-Sadat
collection PubMed
description INTRODUCTION: Superficial morphea (SM) is an uncommon entity that was described in the literature without definitive correlation to localized scleroderma (LS) or other atrophoderma diseases. AIM: To demonstrate the clinicopathological features of SM and evaluate the efficacy of different therapeutic modalities in its management. PATIENTS AND METHODS: A total of 28 patients with SM were studied during the period from 2010 to 2015. Clinicopathological features and therapeutic outcomes were recorded and analyzed. RESULTS: Clinically, SM was predominant in females (71.4%) with an average onset at 33 years of age and an average duration of 15 months. It was commonly presented as asymptomatic, darkly pigmented, and multiple and slightly indurated patches. The lesions were mostly ill-defined, large-sized, and located more on the trunk. Histologically, thickening of collagen fibers was observed either localized to the papillary dermis only (38.9%) or extended into the upper reticular dermis (61.1%). Elastic fibers were generally diminished in the upper reticular dermis while the number of fibroblasts and basal melanin pigmentation were increased in the majority of cases (92.9% and 96.4%, respectively). The most commonly associated diseases were diabetes mellitus (50%) and hepatitis C virus (HCV) infection (42.8%), and their incidence was significantly higher than that in patients with LS. Excimer light showed promising effective results in the treatment of most cases (78.9%) while the response to other modalities such as topical corticosteroid alone or in combination with tacrolimus or treatment with UVA1 alone was less effective (7.1%, 23.1%, and 5%, respectively). CONCLUSION: Our results proposed that SM is a distinctive clinicopathological variant and not a stage in the spectrum of LS. The novel response of SM to excimer light and not for UVA1 therapy also suggests the different therapeutic outcome of SM from LS. Although SM has a significant association with DM and HCV infection, they seem not to affect the course of the disease.
format Online
Article
Text
id pubmed-6770326
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-67703262019-10-22 Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy Mosbeh, Al-Sadat Aboeldahab, Soha El-Khalawany, Mohamed Dermatol Res Pract Research Article INTRODUCTION: Superficial morphea (SM) is an uncommon entity that was described in the literature without definitive correlation to localized scleroderma (LS) or other atrophoderma diseases. AIM: To demonstrate the clinicopathological features of SM and evaluate the efficacy of different therapeutic modalities in its management. PATIENTS AND METHODS: A total of 28 patients with SM were studied during the period from 2010 to 2015. Clinicopathological features and therapeutic outcomes were recorded and analyzed. RESULTS: Clinically, SM was predominant in females (71.4%) with an average onset at 33 years of age and an average duration of 15 months. It was commonly presented as asymptomatic, darkly pigmented, and multiple and slightly indurated patches. The lesions were mostly ill-defined, large-sized, and located more on the trunk. Histologically, thickening of collagen fibers was observed either localized to the papillary dermis only (38.9%) or extended into the upper reticular dermis (61.1%). Elastic fibers were generally diminished in the upper reticular dermis while the number of fibroblasts and basal melanin pigmentation were increased in the majority of cases (92.9% and 96.4%, respectively). The most commonly associated diseases were diabetes mellitus (50%) and hepatitis C virus (HCV) infection (42.8%), and their incidence was significantly higher than that in patients with LS. Excimer light showed promising effective results in the treatment of most cases (78.9%) while the response to other modalities such as topical corticosteroid alone or in combination with tacrolimus or treatment with UVA1 alone was less effective (7.1%, 23.1%, and 5%, respectively). CONCLUSION: Our results proposed that SM is a distinctive clinicopathological variant and not a stage in the spectrum of LS. The novel response of SM to excimer light and not for UVA1 therapy also suggests the different therapeutic outcome of SM from LS. Although SM has a significant association with DM and HCV infection, they seem not to affect the course of the disease. Hindawi 2019-09-19 /pmc/articles/PMC6770326/ /pubmed/31641348 http://dx.doi.org/10.1155/2019/1967674 Text en Copyright © 2019 Al-Sadat Mosbeh et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mosbeh, Al-Sadat
Aboeldahab, Soha
El-Khalawany, Mohamed
Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
title Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
title_full Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
title_fullStr Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
title_full_unstemmed Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
title_short Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
title_sort superficial morphea: clinicopathological characteristics and a novel therapeutic outcome to excimer light therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770326/
https://www.ncbi.nlm.nih.gov/pubmed/31641348
http://dx.doi.org/10.1155/2019/1967674
work_keys_str_mv AT mosbehalsadat superficialmorpheaclinicopathologicalcharacteristicsandanoveltherapeuticoutcometoexcimerlighttherapy
AT aboeldahabsoha superficialmorpheaclinicopathologicalcharacteristicsandanoveltherapeuticoutcometoexcimerlighttherapy
AT elkhalawanymohamed superficialmorpheaclinicopathologicalcharacteristicsandanoveltherapeuticoutcometoexcimerlighttherapy